Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA Big Molecule WatchOn July 24, 2026, Outlook Therapeutics, Inc.OphthalmologyRead full story pharminent July 31, 2026 (Last updated: August 3, 2026) Big Molecule Watch On July 24, 2026, Outlook Therapeutics, Inc. Ophthalmology Read full story Post navigation Previous: J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyoutNext: Novo setback casts doubt on a new way to treat heart disease Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
